ges in the staffing of thoracic medicine over the same period since the retirement of many physicians with long experience of tuberculosis. The treatment of tuberculosis depends not only on the correct prescription of effective chemotherapy regimens but also on the patient's compliance with treatment. Several studies have shown that when treatment is not supervised by thoracic physicians prescription errors and excessive or inadequate treatment occur in an appreciable proportion of patients.5 The patient's compliance is a major determinant of the success of drug treatment, and is more likely to be achieved if the most effective and shortest regimens are prescribed correctly, with treatment monitored, and adjusted if necessary, by an experienced physician. Recent studies have shown problems of compliance and default (10O,,) and drug toxicity (10°O) in adult patients in England and Wales. 6 In view of the development of effective short course regimens and major changes in the staffing of the services that provide tuberculosis treatment, the Joint Tuberculosis Committee of the British Thoracic Society believes that it is now opportune to issue guidelines for the management of tuberculosis in the United Kingdom. Guidelines have been published recently by the American Thoracic Society7 and by the International Union against Tuberculosis and Lung Diseases. 8 The committee considers that treatment of all cases of adult pulmonary tuberculosis should be supervised by physicians in thoracic medicine, and that the drug treatment of all forms of adult non-pulmonary tuberculosis should at the very least be supervised in conjunction with a thoracic physician. The treatment of children should be shared by a paediatrician and a thoracic physician.
Recommended regimens for adults PULMONARY TUBERCULOSIS
A six month regimen, comprising rifampicin, isoniazid, pyrazinamide and ethambutol for the initial two months, followed by rifampicin and isoniazid for a further four months, is recommended standard treatment for adult pulmonary tuberculosis irrespective of the bacteriological state of the sputum. There is evidence that the fourth drug (ethambutol) can be omitted in patients with a low risk of resistance to isoniazid.9 '°This applies to previously untreated patients in Britain.
NON-PULMONARY TUBERCULOSIS
Although there have been relatively few controlled clinical trials in non-pulmonary tuberculosis, the evidence suggests that it can be treated with the same regimens as pulmonary disease." The duration of chemotherapy for some forms of extrapulmonary tuberculosis (described below*), may need to be longer than six months. Non-compliant patients Vagrants, alcoholics, and patients who are mentally ill are unlikely to comply with self medication. These, and others found to be noncompliant, are best given fully supervised chemotherapy regimens. Isoniazid, rifampicin, and pyrazinamide with streptomycin or ethambutol three times weekly for two months, followed by rifampicin and isoniazid three times weekly for four months, are recommended (for dosages see Special precautions and pretreatment screening Renal function should be checked before treatment with steptomytin or ethambutol. If possible the drugs should be avoided in renal failure, but if they are used serum concentrations should be monitored and substantially ,reduced dosages given. Because of the possible (but rare) toxic effects of ethambutol on the eye, it is recommended that visual acuity should be tested by Snellen chart before it is used.38 The drug should be used only in patients who have reasonable visual acuity and who are able to appreciate and report visual symptoms. The notes should record that the patient has been told to report visual symptoms, and the general practitioner should be informed of this. In small children and in those
Meningitis
Liver function should be checked before treatment. Transient increases in hepatic transaminases are common after the start of treatment, and require no action unless the patient has symptoms of hepatitis or jaundice. After the initial measurement liver function does not need to be monitored routinely except in alcoholics and those with other liver diseases. If jaundice or other symptoms of hepatitis develop, all drugs must be stopped. It is usually possible to restart all drugs after liver function has returned to pretreatment levels. If symptoms recur, however, the drugs should be introduced individually, once liver function has returned to normal, at a lower dose initially together with at least one drug that is unlikely to cause hepatic dysfunction (streptomycin or ethambutol non-infectious within two weeks of treatment that contains rifampicin and isoniazid.29 Follow up should be at least monthly initially and then two monthly, the early follow up being important to reinforce education of the patient. Sputum examination for pulmonary disease should be repeated two months before treatment is due to be stopped if the patient's clinical progress is unsatisfactory or where compliance is in doubt. A chest radiograph should be taken at the end of treatment. Clinic nurses or tuberculosis health visitors are extremely important for monitoring patients' compliance and the accuracy and continuity of prescribing, tablet checks and urine tests for rifampicin being carried out during chemotherapy. Monitoring ofnon-pulmonary disease is largely based on clinical assessment and radiography where appropriate.
Failure during chemotherapy or a relapse after treatment in patients prescribed effective regimens is almost invariably due to poor compliance (see below). 45 In cases of multiple drug resistance affecting both rifampicin and isoniazid, treatment should be started with at least three drugs to which the organism is sensitive and continued until sputum cultures become negative, after which two drugs should be continued for at least nine months more. Treatment in such patients has to be planned on an individual basis,30 and may need to include reserve drugs (table 3) . Such treatment must be closely monitored, as full compliance is essential to prevent the emergence of further drug resistance. 4 After treatment Relapse is uncommon in the United Kingdom with the recommended regimen (0-3% of Ormerod 
